Expression of peroxisome proliferator-activated receptor-gamma in the substantia nigra of hemiparkinsonian nonhuman primates

References

• Issemann I, Green S. Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. Nature. 1990;347:645–50.
   PubMed Web of Science ®Google Scholar
• Chew CH, Samian MR, Najimudin N, Tengku-Muhammad TS. Molecular characterisation of six alternatively spliced variants and a novel promoter in human peroxisome proliferator-activated receptor alpha. Biochem Biophys Res Commun. 2003;305:235–43.
   PubMed Web of Science ®Google Scholar
• Larsen PJ, Jensen PB, Sorensen RV, Cooney GJ, Wassermann K, Kraegen EW. Differential influences of peroxisome proliferator-activated receptors gamma and -alpha on food intake and energy homeostasis. Diabetes. 2003;52:2249–59.
   PubMed Web of Science ®Google Scholar
• Bernardo A, Minghetti L. PPAR-gamma agonists as regulators of microglial activation and brain inflammation. Curr Pharm Des. 2006;12:93–109.
   PubMed Web of Science ®Google Scholar
• Kapadia R, Yi JH, Vemuganti R. Mechanisms of anti-inflammatory and neuroprotective actions of PPAR-gamma agonists. Front Biosci. 2008;13:1813–26.
   PubMed Web of Science ®Google Scholar
• Breidert T, Callebert J, Heneka MT, Landreth G, Launay JM, Hirsch EC. Protective action of the peroxisome proliferator-activated receptor-gamma agonist pioglitazone in a mouse model of Parkinson’s disease. J. Neurochem. 2002;82:615–24.
   PubMed Web of Science ®Google Scholar
• Dehmer T, Heneka MT, Sastre M, Dichgans J, Schulz JB. Protection by pioglitazone in the MPTP model of Parkinson’s disease correlates with I kappa B alpha induction and block of NFkappa B and iNOS activation. J Neurochem. 2004;88:494–501.
   PubMed Web of Science ®Google Scholar
• Schintu N, Frau L, Ibba M, Caboni P, Garau A, Carboni E, et al. PPAR-gamma-mediated neuroprotection in a chronic mouse model of Parkinson’s disease. Eur J Neurosci. 2009;29:954–63.
   PubMed Web of Science ®Google Scholar
• Swanson CR, Joers V, Bondarenko V, Brunner K, Simmons HA, Ziegler TE, et al. The PPAR-gamma agonist pioglitazone modulates inflammation and induces neuroprotection in Parkinsonian monkeys. J Neuroinflamm. 2011;8:91.
   PubMed Web of Science ®Google Scholar
• Sadeghian M, Marinova-Mutafchieva L, Broom L, Davis JB, Virley D, Medhurst AD, et al. Full and partial peroxisome proliferation-activated receptor-γ agonists, but not δ agonist, rescue of dopaminergic neurons in the 6-OHDA parkinsonian model is associated with inhibition of microglial activation and MMP expression. J Neuroimmunol. 2012;246:69–77.
   PubMed Web of Science ®Google Scholar
• Zhou J, Wilson KM, Medh JD. Genetic analysis of four novel peroxisome proliferator activated receptor-gamma splice variants in monkey macrophages. Biochem Biophys Res Commun. 2002;293:274–83.
   PubMed Web of Science ®Google Scholar
• McTigue DM, Tripathi R, Wei P, Lash AT. The PPAR gamma agonist pioglitazone improves anatomical and locomotor recovery after rodent spinal cord injury. Exp Neurol. 2007;205:396–406.
   PubMed Web of Science ®Google Scholar
• Schutz B, Reimann J, Dumitrescu-Ozimek L, Kappes-Horn K, Landreth GE, Schurmann B et al. The oral antidiabetic pioglitazone protects from neurodegeneration and amyotrophic lateral sclerosis-like symptoms in superoxide dismutase-G93A transgenic mice. J Neurosci. 2005;25:7805–12.
   PubMed Web of Science ®Google Scholar
• Mandrekar-Colucci S, Karlo JC, Landreth GE. Mechanisms underlying the rapid peroxisome proliferator-activated receptor-gamma-mediated amyloid clearance and reversal of cognitive deficits in a murine model of Alzheimer’s disease. J Neurosci. 2012;32:10117–28.
   PubMed Web of Science ®Google Scholar
• Feinstein DL, Galea E, Gavrilyuk V, Brosnan CF, Whitacre CC, Dumitrescu-Ozimek L, et al. Peroxisome proliferator-activated receptor-gamma agonists prevent experimental autoimmune encephalomyelitis. Ann Neurol. 2002;51:694–702.
   PubMed Web of Science ®Google Scholar
• Geldmacher DS, Fritsch T, McClendon MK, Landreth G. A randomized pilot clinical trial of the safety of piogltiazone in treatment of patients with Alzheimer disease. Arch Neurol. 2011;68:45.
   PubMedGoogle Scholar
• Dupuis L, Dengler R, Heneka MT, Meyer T, Zierz S, Kassubek J, et al. A randomized, double blind, placebo-controlled trial of pioglitazone in combination with riluzole in amyotrophic lateral sclerosis. PLoS ONE. 2012;7:e37885.
   PubMed Web of Science ®Google Scholar
• Shukla DK, Kaiser CC, Stebbins GT, Feinstein DL. Effects of pioglitazone on diffusion tensor imaging indices in multiple sclerosis patients. Neurosci Lett. 2010;472:153–6.
   PubMed Web of Science ®Google Scholar
• NINDS NIH Exploratory Trials in Parkinson’s Disease. Pioglitazone in early Parkinson’s disease (FS-ZONE) [Internet]. Bethesda (MD): NINDS [cited 2010 Oct 2]. Available from: http://www.parkinsontrial.ninds.nih.gov/netpd-fs-zone.html
   Google Scholar
• Moreno S, Farioli-Vecchioli S, Ceru MP. Immunolocalization of peroxisome proliferator-activated receptors and retinoid X receptors in the adult rat CNS. Neuroscience. 2004;123:131–45.
   PubMed Web of Science ®Google Scholar
• Emborg ME. Nonhuman primate models of Parkinson’s disease. ILAR J. 2007;48:339–55.
   PubMed Web of Science ®Google Scholar
• Emborg ME, Carbon M, Holden JE, During MJ, Ma Y, Tang C, et al. Subthalamic glutamic acid decarboxylase gene therapy: changes in motor function and cortical metabolism. J Cereb Blood Flow Metab. 2007;27:501–9.
   PubMed Web of Science ®Google Scholar
• Emborg ME, Zhang Z, Joers V, Brunner K, Bondarenko V, Ohshima S, et al. Intracerebral transplantation of differentiated human embryonic stem cells to hemiparkinsonian monkeys. Cell Transplant. 2013;22:831–8.
   PubMed Web of Science ®Google Scholar
• Paxinos G. The rhesus monkey brain in stereotaxic coordinates. Waltham, MA: Academic Press; 2000.
   Google Scholar
• Braissant O, Foufelle F, Scotto C, Dauca M, Wahli W. Differential expression of peroxisome proliferator-activated receptors (PPARs): tissue distribution of PPAR-alpha, -beta, and -gamma in the adult rat. Endocrinology. 1996;137:354–66.
   PubMed Web of Science ®Google Scholar
• Cullingford TE, Bhakoo K, Peuchen S, Dolphin CT, Patel R, Clark JB. Distribution of mRNAs encoding the peroxisome proliferator-activated receptor alpha, beta, and gamma and the retinoid X receptor alpha, beta, and gamma in rat central nervous system. J Neurochem. 1998;70:1366–75.
   PubMed Web of Science ®Google Scholar
• Gofflot F, Chartoire N, Vasseur L, Heikkinen S, Dembele D, Le Merrer J, et al. Systematic gene expression mapping clusters nuclear receptors according to their function in the brain. Cell. 2007;131:405–18.
   PubMed Web of Science ®Google Scholar
• McKay BE, Molineux ML, Turner RW. Endogenous biotin in rat brain: Implications for false-positive results with avidin-biotin and streptavidin-biotin techniques. Methods Mol Biol. 2008;418:111–28.
   PubMedGoogle Scholar
• Swanson C, Du E, Johnson D, Johnson JA, Emborg ME. Neuroprotective properties of a novel non-thiazoledinedione partial PPAR-gamma agonist against MPTP. PPAR Res. 2013;2013:582809.
   PubMed Web of Science ®Google Scholar
• Guttman M, Fibiger HC, Jakubovic A, Calne DB. Intracarotid 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine administration: biochemical and behavioral observations in a primate model of hemiparkinsonism. J Neurochem. 1990;54:1329–34.
   PubMed Web of Science ®Google Scholar
• Carta AR</author>, Frau L, Pisanu A, Wardas J, Spiga S, Carboni E. Rosiglitazone decreases peroxisome proliferator receptor-gamma levels in microglia and inhibits TNF-alpha production: New evidences on neuroprotection in a progressive Parkinson’s disease model. Neuroscience. 2011;194:250–61.
   PubMed Web of Science ®Google Scholar
• Eberling JL, Bankiewicz KS, Jordan S, VanBrocklin HF, Jagust WJ. PET studies of functional compensation in a primate model of Parkinson’s disease. Neuroreport. 1997;8:2727–33.
   PubMed Web of Science ®Google Scholar
• Emborg-Knott ME, Domino EF. MPTP-induced hemiparkinsonism in nonhuman primates 6–8 years after a single unilateral intracarotid dose. Exp Neurol. 1998;152:214–20.
   PubMed Web of Science ®Google Scholar